Comment on: Possible increased risk of Epstein-Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients.

Prevymis (letermovir) - Merck (MSD)

Comment on: Possible increased risk of Epstein-Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients. (PubMed, J Antimicrob Chemother) - Mar 4, 2026 - No abstract available
Journal • Epstein-Barr Virus Infections • Infectious Disease • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/41778970

Jan Styczynski

Mar 4, 2026